Thesis pillars
- Declining Revenue Weak Quality→Stable
- Large Analyst Upside Gap→Stable
- Insider Accumulation→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 4, 2026
Apnimed, Inc. (APMD) Stock Analysis
Range Bound setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Multiple concerning factors at $19.15: Leverage penalty (D/E 1.3): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2).
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA)... Read more
Sell if holding. Multiple concerning factors at $19.15: Leverage penalty (D/E 1.3): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2). Chart setup: RSI 55 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Apnimed, Inc.
Latest news
- NEWS APMD SWOT Analysis: Financial Resilience Amidst Challenges Revea - GuruFocus — GuruFocus neutral
- NEWS Apnimed (APMD) Insider Trading Activity 2026 - MarketBeat — MarketBeat neutral
- NEWS Apnimed Q2 Results: EPS beats estimates, sales at $12.08M - scanx.trade — scanx.trade positive
- NEWS Apnimed Q2FY26 Results: Net income turns positive at $125.9 million - scanx.trade — scanx.trade positive
- NEWS Apnimed (APMD) Earnings Date and Reports 2026 - MarketBeat — MarketBeat neutral
Generated 2026-10-29T11:08:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -29.4% YoY. Growth thesis broken unless recovery story develops.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $19.15: Leverage penalty (D/E 1.3): -0.5; V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2). Chart setup: RSI 55 mid-range, Bollinger mid-band. Prior stop was $17.81. Score 5.2/10, moderate confidence.
Analyst target: $42.78 (+123.4% upside). Prior stop was $17.81. Stop-loss: $17.81.
V7 low-quality RISK_OFF penalty: -0.5 (Q=5.2); Leverage penalty (D/E 1.3): -0.5; Weak growth.
Apnimed, Inc. trades at a P/E of 2.7 (forward -4.8). TrendMatrix value score: 7.5/10. Verdict: Sell.
10 analysts cover APMD with a consensus score of 4.2/5. Average price target: $50.
What does Apnimed, Inc. do?Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that...
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.